Pyrotinib in Women With High-risk in Early Stage Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: Pyrotinib
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Collaborators: Jiangsu HengRui Medicine Co., Ltd.